Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2019-04-03 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Closure of Trading Window
Regulatory Filings
2019-04-03 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the closure of the trading window for insiders ahead of the announcement of audited financial results for the quarter and year ended March 31, 2019. It references compliance with SEBI regulations and mentions the upcoming board meeting date will be intimated later. There is no actual financial data, report, or detailed financial analysis included. The document is essentially a regulatory announcement related to insider trading restrictions prior to financial results disclosure. Given the short length (1378 characters) and the nature of the content, this fits best as a Regulatory Filing (RNS) rather than a financial report or earnings release.
2019-04-03 English
Buyback
Transaction in Own Shares Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the buyback of shares by Natco Pharma Limited. It includes details about the reconciliation of share capital pre and post extinguishment of shares, referencing the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018. The content focuses on reporting the status of share capital changes due to buyback activities, which aligns with announcements related to share repurchase or capital changes. The document length is short (1481 characters), and it is not a full financial report or earnings release but a specific update on share capital changes due to buyback. Therefore, the appropriate classification is Transaction in Own Shares (POS).
2019-03-29 English
Axis Capital Ltd ("Manager to the Buyback Offer") has submitted to BSE a copy of Corrigendum to the Public Announcement dated November 06, 2018 for the attention of the Equity Shareholders/Beneficial
Regulatory Filings
2019-03-18 English
Buyback
Transaction in Own Shares Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited regarding a buyback of equity shares by Natco Pharma Limited. It references a Public Announcement and a Corrigendum related to the buyback process, including publication details in newspapers. The content focuses on the announcement and procedural updates about the buyback, not on the buyback report or financial statements themselves. The document length is short (2228 characters), and it serves as an official notification or update rather than a detailed financial report. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares.
2019-03-15 English
CORRIGENDUM TO THE PUBLIC ANNOUNCEMENT DATED NOVEMBER 6, 2018 FOR THE ATTENTION OF THE EQUITY SHAREHOLDERS FOR THE BUY-BACK OF EQUITY SHARES FROM THE OPEN MARKET
Regulatory Filings
2019-03-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.